Nautilus Biotechnology, Inc. (NAUT) - Q2 2024 Filing Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2024. Nautilus Biotechnology, Inc. is a development-stage life sciences company focused on creating a proteomics platform (the "Nautilus platform") to quantify and analyze the proteome. The company has not yet commercialized any products and has not generated any revenue since inception. It operates as a single reporting segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(18,010) | $(15,808) | $(36,740) | $(30,773) |
| Net Loss Per Share (Basic & Diluted) | $(0.14) | $(0.13) | $(0.29) | $(0.25) |
| Operating Expenses | $20,789 | $19,016 | $42,396 | $37,076 |
| Interest Income | $2,798 | $3,222 | $5,675 | $6,320 |
| Cash, Cash Equivalents & Investments | $232.9 million (as of June 30, 2024) | |||
| Accumulated Deficit | $239.0 million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by 9% ($1.8 million) in Q2 2024 compared to Q2 2023, and by 14% ($5.3 million) for the six-month period.
- Research & Development (R&D): Increased 4% in Q2 and 11% YTD, driven by higher salaries, benefits, stock-based compensation, and laboratory supplies due to increased headcount.
- General & Administrative (G&A): Increased 18% in Q2 and 19% YTD, primarily due to higher professional fees (legal/audit) and increased personnel costs.
- Interest Income: Decreased 13% in Q2 and 10% YTD compared to the prior year periods, reflecting a lower average balance of cash and investments.
- Liquidity: Net cash used in operating activities was $31.7 million for the six months ended June 30, 2024, compared to $26.1 million in the prior year period. Net cash provided by investing activities was $36.6 million in the current period (driven by maturities of securities), compared to a net use of $15.8 million in the prior year.
Guidance, Outlook, and Risks
- Commercialization Plan: The company is executing a three-phase commercial launch plan. It is currently in the collaboration phase with biopharmaceutical companies and key opinion leaders. The early access limited release phase is anticipated in 2025, with a broader commercial launch expected to follow. No material revenue is anticipated from early access activities.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and short-term investments ($232.9 million) are sufficient to fund operations for at least the next 12 months. The company has an "at-the-market" equity offering program with Cowen and Company but has not sold shares under it in the first half of 2024.
- Legal Proceedings: The company is involved in patent litigation against Somalogic (Standard Biotools) and the California Institute of Technology regarding US Patent No. 7,842,793. The proceedings were temporarily stayed in May 2024. Management believes it will prevail but notes the unpredictability of litigation.
- Risk Factors: Key risks include the failure to successfully develop or commercialize the Nautilus platform, dependence on third-party suppliers for critical components, potential inability to raise additional capital, and the impact of global economic conditions on research spending.
Investor Verification Checklist
- Verify the timeline and milestones for the transition from the collaboration phase to the early access phase in 2025.
- Monitor the status of the patent litigation against Somalogic/Standard Biotools and any potential financial impact.
- Assess the burn rate relative to the $232.9 million cash position to confirm the 12-month liquidity runway.
- Review the company's progress in securing manufacturing partners and supply chain stability for complex reagents and antibodies.
- Track any future equity issuances under the "at-the-market" sales agreement and their impact on shareholder dilution.